miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 31, 2026

The Sell-Off In Gold May Be Last Stop Before $10,000 – 5 Stocks and an ETF To Buy Now

View original at finance.yahoo.com
The Sell-Off In Gold May Be Last Stop Before $10,000 – 5 Stocks and an ETF To Buy Now The case for gold and gold miners is compelling for two reasons…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The demand for Gold will remain consistent over the next 5 to 10 years, according to some opinions from Wall Street

    80% confidence
  • Silver is not considered as much of an asset hedge or a store of value like gold

    80% confidence
  • In the long term, analysts expect gold to trade between $10,000 and $16,150 over the next 10 years

    80% confidence
  • Gold will reach $10,000 per ounce by 2028

    80% confidence
  • Diversification away from U.S. dollar reserve holdings, while still moderate, has accelerated in recent years

    80% confidence
  • Agnico Eagle Mines rated Buy

    80% confidence
  • Barrick Gold rated Buy

    80% confidence
  • Gold could reach $10,000 per ounce before the end of the decade if it continues on its current path

    80% confidence
  • Wheaton Precious Metals rated Buy

    80% confidence
  • Newmont Corporation rated Outperform

    80% confidence
  • Franco-Nevada rated Buy

    80% confidence
  • The most powerful structural force is the global shift in reserve holdings, with central banks continuing to increase the percentage of gold in their international reserves

    80% confidence
  • Gold will reach $5,000 per ounce by 2026

    80% confidence

Data points we hold from this source

UBS Group AG · target price270 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Sell-Off In Gold May Be Last Stop Before $10,000 – 5 Stocks and an ETF To Buy Now — Source | Via News | es.VIA.NEWS